CymaBay Therapeutics, Inc. (NASDAQ:CBAY) went down by -7.95% from its latest closing price when compared to the 1-year high value of $14.00 and move down -764.2%, while CBAY stocks collected +21.80% of gains with the last five trading sessions. Press Release reported on 11/25/19 that CymaBay Therapeutics Halts Clinical Development of Seladelpar

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Worth an Investment?

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) The 36 Months beta value for CBAY stocks is at 0.99, while of the analysts out of 0 who provided ratings for CymaBay Therapeutics, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $2.31 which is $0.69 above current price. CBAY currently has a short float of 12.40% and public float of 61.11M with average trading volume of 1.42M shares.

CBAY Market Performance

CBAY stocks went down by -70.81% for the week, with the monthly drop of -63.92% and a quarterly performance of -72.86%, while its annual performance rate touched -82.02%. The simple moving average for the period of the last 20 days is -65.28% for CBAY stocks with the simple moving average of -80.61% for the last 200 days.

Analysts’ Opinion on CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Many brokerage firms have already submitted their reports for CBAY stocks, with ROTH Capital repeating the rating for CBAY shares by setting it to “Neutral”. The predicted price for CBAY socks in the upcoming period according to ROTH Capital is $2 based on the research report published on November 26, 2019.

Raymond James, on the other hand, stated in their research note that they expect to see CBAY stock at the price of $2. The rating they have provided for CBAY stocks is “Mkt Perform” according to the report published on November 26, 2019.

H.C. Wainwright gave “ Neutral” rating to CBAY stocks, setting the target price at $2 in the report published on November 26, 2019.

CBAY Stocks -66.26% Far from 50 Day Moving Average

After a stumble in the market that brought CBAY to its low price for the period of the last 52 weeks, CymaBay Therapeutics, Inc. was unable to take a rebound, for now settling with -88.43% of loss for the given period.

The stock volatility was left at 10.50%, however, within the period of a single month, the volatility rate increased by 17.85%, while the shares sank at the distance of -67.34% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -71.23% lower at the present time.

In the course of the last 5 trading sessions, CBAY went up by +21.80%, which changed the moving average for the period of 200 days to the total of -83.72% of losses for the stock in comparison to the 20-day moving average settled at $4.50. In addition, CymaBay Therapeutics, Inc. saw -79.42% in overturn over the period of a single year with a tendency to cut further losses.

CBAY Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at CymaBay Therapeutics, Inc. (CBAY), starting from Shah Sujal, who bought 5,000 shares at the price of $4.30 back on Oct 10. After this action, Rushing now owns 120,000 shares of CymaBay Therapeutics, Inc., valued at $21,500 with the latest closing price.

Shah Sujal, the Chief Executive Officer of CymaBay Therapeutics, Inc., bought 3,100 shares at the value of $5.55 during a trade that took place back on Sep 23, which means that Shah Sujal is holding 115,000 shares at the value of $17,205 based on the most recent closing price.